Triplet therapy in metastatic castrate sensitive prostate cancer (mCSPC)—A potential new standard of care
A Mittal, SS Sridhar, M Ong, DM Jiang - Current Oncology, 2023 - mdpi.com
The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has
evolved rapidly in the past decade with the approval of several life-prolonging therapies …
evolved rapidly in the past decade with the approval of several life-prolonging therapies …
Population-based study of docetaxel or abiraterone effectiveness and predictive markers of progression free survival in metastatic castration-sensitive prostate cancer
Background Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with
metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among …
metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among …
Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer
R Pelloux-Prayer, P Schiele, S Oudard, G Gravis… - Clinical Genitourinary …, 2021 - Elsevier
Background The optimal therapeutic strategies for patients with metastatic hormone-
sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer …
sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer …
A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer
A Parmar, N Timilshina, U Emmenegger… - Canadian …, 2021 - pmc.ncbi.nlm.nih.gov
Introduction Earlier application of oral androgen receptor-axis-targeted therapies in patients
with metastatic castration-sensitive prostate cancer (mCSPC) has established improvements …
with metastatic castration-sensitive prostate cancer (mCSPC) has established improvements …
Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer
M Wenzel, B Hoeh, C Humke, C Cano Garcia… - World Journal of …, 2024 - Springer
Purpose No currently available phase III trial compared docetaxel vs. androgen receptor
pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone …
pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone …
Cost-effectiveness analysis for therapy sequence in advanced cancer: A microsimulation approach with application to metastatic prostate cancer
Purpose Patients with advanced cancer may undergo multiple lines of treatment, switching
therapies as their disease progresses. We developed a general microsimulation framework …
therapies as their disease progresses. We developed a general microsimulation framework …
Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations
R Pelloux-Prayer, T Bataillard… - Clinical Genitourinary …, 2022 - Elsevier
The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC)
has been significantly modified by the availability of innovative but expensive treatments …
has been significantly modified by the availability of innovative but expensive treatments …
An Economic Evaluation of Docetaxel Versus Abiraterone or Enzalutamide in Addition to Androgen Deprivation Therapy for the First-Line Treatment of Metastatic …
T Papastavros - 2022 - search.proquest.com
Background: Prostate cancer is a leading cause of cancer morbidity and mortality in
Canada. Docetaxel, abiraterone, and enzalutamide have demonstrated survival benefits …
Canada. Docetaxel, abiraterone, and enzalutamide have demonstrated survival benefits …
[HTML][HTML] CADTH Health Technology Review Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer
A Shane, M Walter - canjhealthtechnol.ca
Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer CADTH Health
Technology Review Abiraterone Acetate for Metastatic Castration-Sensitive Prostate …
Technology Review Abiraterone Acetate for Metastatic Castration-Sensitive Prostate …